Patent application number | Description | Published |
20120011156 | INTER-CLASS MOLECULAR ASSOCIATION CONNECTIVITY MAPPING - Methods, systems, devices and/or apparatuses are provided for computationally deriving molecular association connectivity maps for the study of inter-class molecular associations in toxicogenomics and drug discovery applications. The inter-class molecular associations can be between at least one bio-molecular entity and at least one therapeutic agent. The methods, systems, devices and/or apparatuses apply integrated molecular interaction network mining and text mining techniques. | 01-12-2012 |
20130058863 | 4-Protein Biomarker Panel for the Diagnosis of Lymphoma from Biospecimen - A panel of lymphoma related biomarkers are provided. The panel allows the identification of a subject at risk for a lymphoma. Further provided are methods of optimizing therapeutic efficacy associated with treatment of a lymphoma related disorder. Methods of identifying biomarkers affiliated with a condition of interest are provided. | 03-07-2013 |
20130144584 | NETWORK MODELING FOR DRUG TOXICITY PREDICTION - A computational systems pharmacology framework consisting of statistical modeling and machine learning based on comprehensive integration of systems biology data, including drug target data, protein-protein interaction (PPI) networks, and gene ontology (GO) annotations, and reported drug side effects, can predict drug toxicity or drug adverse reactions (ADRs). Biomolecular network and gene annotation information can significantly improve the predictive accuracy of ADR of drugs under development. The use of PPI networks can increase prediction specificity, and the use of GO annotations can increase prediction sensitivity. | 06-06-2013 |
20130144882 | MULTIDIMENSIONAL INTEGRATIVE EXPRESSION PROFILING FOR SAMPLE CLASSIFICATION - An organized knowledge-supervised approach—Multidimensional Integrative eXpression Profiling (MIXP)—can not only improve sample classification accuracy by serving as a feature transformation approach, but also help in the discovery of groups of crucial molecular entities that have been too weak to detect individually through preexisting methods. Functionally related molecules that are individually expressed with low differentials, have often been considered as noise and ignored in traditional studies, but through the MIXP approach, they can be readily identified by virtue of their coordinate expression. | 06-06-2013 |
20130144887 | INTEGRATIVE PATHWAY MODELING FOR DRUG EFFICACY PREDICTION - An integrative pathway modeling approach and ranking/evaluating algorithms based on disease-specific pathway models can predict drug efficacy for patients based on their gene expression profiles. A disease-specific pathway model is first constructed with proteins and drugs important to the disease by using computational connectivity maps (C-Maps). Through the pathway model-based ranking algorithm, ideal drugs or optimized drug combination can be discovered for a patient to modulate the gene expression profile of this patient close to those in healthy individuals at pathway-level. | 06-06-2013 |
20140046962 | INTER-CLASS MOLECULAR ASSOCIATION CONNECTIVITY MAPPING - Methods, systems, devices and/or apparatuses are provided for computationally deriving molecular association connectivity maps for the study of inter-class molecular associations in toxicogenomics and drug discovery applications. The inter-class molecular associations can be between at least one bio-molecular entity and at least one therapeutic agent. The methods, systems, devices and/or apparatuses apply integrated molecular interaction network mining and text mining techniques. | 02-13-2014 |
20150119289 | METHODS TO DETERMINE CANDIDATE BIOMARKER PANELS FOR A PHENOTYPIC CONDITION OF INTEREST - A panel of lymphoma related biomarkers are provided. The panel allows the identification of a subject at risk for a lymphoma. Further provided are methods of optimizing therapeutic efficacy associated with treatment of a lymphoma related disorder. Methods of identifying biomarkers affiliated with a condition of interest are provided. | 04-30-2015 |
20150371009 | DRUG IDENTIFICATION MODELS AND METHODS OF USING THE SAME TO IDENTIFY COMPOUNDS TO TREAT DISEASE - Drug identification models and methods of using the same to identify compounds to treat disease. In at least one method of the present disclosure, at least one first drug/compound which is not actively approved by a governmental regulatory entity to treat a targeted disease or condition, which was not previously approved to treat the targeted disease or condition, and which was not previously withdrawn from clinical testing in connection with the targeted disease or condition is tested within a framework configured using drug/compound data from actively approved drugs/compounds and withdrawn drugs/compounds in attempt to identify at least one candidate drug/compound to treat the targeted disease or condition. | 12-24-2015 |
Patent application number | Description | Published |
20110227648 | Silicon-on-Insulator High Power Amplifiers - Illustrative embodiments of a power amplifier are disclosed which include a plurality of amplifier cells, each having an input and an output. The plurality of amplifier cells are formed on a semiconductor substrate such that the outputs of the plurality of amplifier cells are electrically coupled in series. Each of the plurality of amplifier cells may comprise a first transistor that is electrically insulated from the semiconductor substrate and a first feedback resistor configured to dynamically bias the first transistor. | 09-22-2011 |
20130120065 | Silicon-on-Insulator High Power Amplifiers - Illustrative embodiments of power amplifiers are disclosed. In one embodiment, a power amplifier includes a plurality of transistors formed on a silicon-on-insulator (SOI) substrate such that the plurality of transistors are each electrically isolated from one another within the SOI substrate. The power amplifier also includes a plurality of biasing networks, each biasing network being configured to dynamically bias at least one of the plurality of transistors. The plurality of transistors are electrically coupled in a series stack, with an output of the power amplifier being provided across the series stack. | 05-16-2013 |
20130307626 | Silicon-on-Insulator High Power Amplifiers - Illustrative embodiments of power amplifiers and associated methods are disclosed. In at least one embodiment, a method may include fabricating a power amplifier in a first silicon layer of a silicon-on-insulator (SOI) substrate, wherein the SOI substrate comprises the first silicon layer, a second silicon layer, and a buried oxide layer disposed between the first and second silicon layers; removing at least some of the second silicon layer from the SOI substrate, after fabricating the power amplifier; and securing the SOI substrate, after removing at least some of the second silicon layer, to an electrically non-conductive and thermally conductive substrate. | 11-21-2013 |
Patent application number | Description | Published |
20100268289 | METHOD AND SYSTEM FOR THE PREDICTION OF CARDIAC ARRHYTHMIAS, MYOCARDIAL ISCHEMIA, AND OTHER DISEASED CONDITION OF THE HEART ASSOCIATED WITH ELEVATED SYMPATHETIC NEURAL DISCHARGES - Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges. | 10-21-2010 |
20110218415 | SYSTEM AND METHOD FOR DETECTING CARDIAC ARRHYTHMIAS FROM HEART NERVE ACTIVITY - A method has been developed that detects cardiac arrhythmia from intrinsic cardiac nerve signals obtained from a heart in a patient. The method includes sampling intrinsic cardiac nerve activity at a high sample rate, filtering the sampled signal with a high pass filter, comparing the filtered signal to a predetermined threshold, and initiating a therapeutic action in response to the filtered signal exceeding the predetermined threshold. The intrinsic cardiac nerve activity may be received through an electrode implanted on the heart or from an electrode inserted into the venous structure of the heart. | 09-08-2011 |
20130184775 | LONG TERM VAGAL NERVE STIMULATION FOR THERAPEUTIC AND DIAGNOSTIC TREATMENT - A method of nerve stimulation produces therapeutic effects in an organ not directly innervated by the electrically stimulated nerve. The method includes identifying an electrical stimulation reaction threshold of at least one organ directly innervated by a parasympathetic nerve of a subject, identifying a reaction threshold of at least one tissue that is not directly innervated by the parasympathetic nerve of the subject after the parasympathetic nerve is electrically stimulated, and electrically stimulating the parasympathetic nerve with an electrical stimulation signal that is below the identified reaction threshold for the at least one directly innervated organ, but above a reaction threshold for the at least one tissue or organ that is not directly innervated by the parasympathetic nerve of the subject. | 07-18-2013 |
20130190586 | Multi-Terminal Nanoelectrode Array - An electrode for monitoring nerve activity has been developed. The electrode includes an array of electrically conductive projections extending from a surface of an electrical contact that enable the electrical contact to be connected directly to the nerve. | 07-25-2013 |
20140357724 | BETA 2 ADRENOCEPTOR ANTAGONISTS FOR TREATING ORTHOSTATIC HYPOTENSION - Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol. | 12-04-2014 |
20150297104 | SYSTEM AND METHOD FOR NON-INVASIVE AUTONOMIC NERVE ACTIVITY MONITORING - A system and method for monitoring nerve activity in a subject. The system includes a plurality of electrodes placed in proximity to skin of the subject, an amplifier electrically connected to the electrodes and configured to generate a plurality of amplified signals corresponding to electrical signals received from the subject through the electrodes, and a signal processor. The signal processor applies a high-pass filter to the amplified signals to generate filtered signals from the amplified signals, identifies autonomic nerve activity in the plurality of filtered signals; and generates an output signal corresponding to the filtered signals. The high-pass filter attenuates a plurality of the amplified signals having frequencies that correspond to heart muscle activity during a heartbeat. | 10-22-2015 |
20160045121 | System and Method for Monitoring Renal Sympathetic Nerve Activity - A system and method for monitoring sympathetic nerve activity (SNA) includes obtaining nerve recordings from a subject using electrodes implanted to acquire signals from arteries or veins associated with sympathetic nerve activity of the subject and comparing the nerve recordings against at least one of pre-operative nerve recordings and post-operative nerve recordings to detect residual nerve activity of the subject. | 02-18-2016 |
Patent application number | Description | Published |
20100137583 | Peptidomimetic protease inhibitors - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 06-03-2010 |
20120064034 | Peptidomimetic protease inhibitors - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 03-15-2012 |
20120282219 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 11-08-2012 |
20140294763 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 10-02-2014 |
Patent application number | Description | Published |
20090012558 | FISTULA GRAFTS HAVING A DEFLECTABLE GRAFT BODY PORTION - This invention provides, in certain aspects, unique devices and methods for treating fistulae. In one embodiment, an inventive device includes an elongate graft body having a proximal end and a distal end. The graft body is configurable to a first condition and a second condition, the second condition including the distal end deflected laterally relative to its position in the first condition of the body. The device also includes a tether, which is connected to the graft body, and is configured to traverse proximally along the body. The tether is manipulable to convert the graft body from the first condition to the second condition. Such a device may also include one or more additional tethers connected to the graft body. For instance, a second tether can be configured to extend distally from the distal end of the graft body, and may be effective in pulling the graft body along a fistula tract. | 01-08-2009 |
20090125119 | FISTULA GRAFTS AND RELATED METHODS AND SYSTEMS USEFUL FOR TREATING GASTROINTESTINAL AND OTHER FISTULAE - Described are medical graft products, systems, and methods useful for treating fistulae, particularly enterocutaneous fistulae. Certain products of the invention are configured to have portions residing in and around a primary fistula opening in a wall of the alimentary canal. One such product includes a biocompatible graft body which is configured to block at least the primary opening. The graft body includes a capping member connected to an elongate plug member. The capping member is configured to contact portions of the alimentary canal wall adjacent to the primary opening, and the elongate plug member is configured to extend into at least a portion of the fistula. A graft product of this sort may be particularly adapted to allow a portion of the capping member to be positioned alongside an exterior, lateral surface of the plug member, e.g., when placed in a delivery device lumen. Such a capping member may be hingedly or non-hingedly coupled to the elongate plug member. | 05-14-2009 |
20110093088 | SELF DEPLOYING IMPLANT IN NEEDLE - Described, in certain inventive embodiments, are unique devices and methods for introducing implants into soft tissue of a patient. One of these devices includes a tissue-penetrating member that is configured to pass in its entirety through a volume of patient tissue. The tissue-penetrating member has a leading end and a trailing end, and provides a receiving space for receipt of an implant body portion for carrying the implant body portion into the volume of patient tissue. The device also includes an implant that has an implant body portion removably received in the receiving space of the tissue-penetrating member. The implant body portion is configured for deployment from the receiving space in the volume of patient tissue so as to remain deployed there along a passageway traversed by the tissue-penetrating member. | 04-21-2011 |
20120323271 | FISTULA CLOSURE DEVICES AND METHODS - Described are methods and systems for treating fistulae and other passageways and openings in the body. In certain aspects, an anchored suture is provided that extends from at or near a first fistula opening and through a fistula tract toward a second fistula opening. Various modes of anchoring may be used in this regard including, in some modes, having the suture extend from a deployed anchoring member positioned in and/or around the first opening. The anchored suture, which has a more slender cross sectional dimension relative to the fistula tract through which it extends, is capable of receiving an optional fill substance therealong in the tract. A fill substance can be or include a variety of biodegradable and/or non-biodegradable objects and materials including flowable and non-flowable materials. | 12-20-2012 |
Patent application number | Description | Published |
20090069677 | SYSTEM AND METHOD FOR TISSUE CHANGE MONITORING DURING HIFU TREATMENT - A method and apparatus is disclosed for determining the presence of tissue change due to exposure to HIFU Therapy. | 03-12-2009 |
20100022921 | ULTRASOUND PHASED ARRAYS - Ultrasound transducers are disclosed which focus acoustic energy at various focal locations while minimizing focal spot degradation and the generation of unwanted on-axis or off-axis energy concentrations through using a generally constant f-number at the various focal locations. | 01-28-2010 |
20100092424 | Method of diagnosis and treatment of tumors using high intensity focused ultrasound - A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response. | 04-15-2010 |
20110201976 | LAPAROSCOPIC HIFU PROBE - A high-intensity focused ultrasound ablation of tissue using minimally invasive medical procedures is provided. | 08-18-2011 |
20120035473 | LAPAROSCOPIC HIFU PROBE - A high-intensity focused ultrasound ablation of tissue using minimally invasive medical procedures is provided. | 02-09-2012 |
20120150035 | Method and Apparatus for the Selective Treatment of Tissue - A HIFU System ( | 06-14-2012 |
20130018260 | METHOD OF DIAGNOSIS AND TREATMENT OF TUMORS USING HIGH INTENSITY FOCUSED ULTRASOUND - A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response. | 01-17-2013 |
20140378832 | METHOD OF DIAGNOSIS AND TREATMENT OF TUMORS USING HIGH INTENSITY FOCUSED ULTRASOUND - A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response. | 12-25-2014 |
Patent application number | Description | Published |
20140075183 | SECURE AND SCALABLE MAPPING OF HUMAN SEQUENCING READS ON HYBRID CLOUDS - System and methods are provided for performing privacy-preserving, high-performance, and scalable DNA read mapping on hybrid clouds including a public cloud and a private cloud. The systems and methods offer strong privacy protection and have the capacity to process millions of reads and allocate most of the workload to the public cloud at a small overall cost. The systems and methods perform seeding on the public cloud using keyed hash values of individual sequencing reads' seeds and then extend matched seeds on the private cloud. The systems and methods are designed to move the workload of read mapping from the extension stage to the seeding stage, thereby ensuring that the dominant portion of the overhead is shouldered by the public cloud. | 03-13-2014 |
20150264077 | Computer Implemented Techniques for Detecting, Investigating and Remediating Security Violations to IT Infrastructure - A method includes collecting system calls and call parameters invoked by monitored applications for target computer systems. The system calls and call parameters are received from operating system kernels on the plurality of target computer systems. Sequences of systems calls and call parameters of the monitored applications are correlated among different target computer systems to deduce malicious activities. Remedial action(s) are performed in response to malicious activities being deduced as being malicious by the correlating. Another method includes determining that network activity at a specific time is deemed to be suspicious. Using IP addresses involved in the suspicious network activity, computer system(s) are determined that are sources of the suspicious network activity. Based on the specific time and the determined computer system(s), application(s) are determined that are executing on the determined computer system(s) that are causing the suspicious network activity. Remedial action(s) are performed for the determined computer system(s). | 09-17-2015 |
20160110500 | SECURE AND SCALABLE MAPPING OF HUMAN SEQUENCING READS ON HYBRID CLOUDS - System and methods are provided for performing privacy-preserving, high-performance, and scalable DNA read mapping on hybrid clouds including a public cloud and a private cloud. The systems and methods offer strong privacy protection and have the capacity to process millions of reads and allocate most of the workload to the public cloud at a small overall cost. The systems and methods perform seeding on the public cloud using keyed hash values of individual sequencing reads' seeds and then extend matched seeds on the private cloud. The systems and methods are designed to move the workload of read mapping from the extension stage to the seeding stage, thereby ensuring that the dominant portion of the overhead is shouldered by the public cloud. | 04-21-2016 |
Patent application number | Description | Published |
20100185336 | INTEGRATED AND OPTIMIZED DISTRIBUTED GENERATION AND INTERCONNECT SYSTEM CONTROLLER - Systems and methods for designing and controlling distributed generation resources are disclosed. Monolithic or distributed controllers control the power requests sent to each distributed generation resource to achieve optimal efficiency using rule-based and/or fuzzy logic-based control techniques. High-impedance fault (HIF) detection circuitry allows power export to the utility grid in normal operating circumstances, and when an islanding condition is detected, ceases that export within two seconds and prevents further export until the condition is cleared. | 07-22-2010 |
20110166716 | INTEGRATED AND OPTIMIZED DISTRIBUTED GENERATION AND INTERCONNECT SYSTEM CONTROLLER - Systems and methods for designing and controlling distributed generation resources are disclosed. Monolithic or distributed controllers control the power requests sent to each distributed generation resource to achieve optimal efficiency using rule-based and/or fuzzy logic-based control techniques. High-impedance fault (HIF) detection circuitry allows power export to the utility grid in normal operating circumstances, and when an islanding condition is detected, ceases that export within two seconds and prevents further export until the condition is cleared. | 07-07-2011 |
20130135110 | ADVANCED BATTERY EARLY WARNING AND MONITORING SYSTEM - Systems, apparatuses and methods for detecting internal cell faults using online and real-time sensing techniques, and providing an accurate and reliable early warning for the incoming failure of battery cells hours or days prior to failure. A system is configured to perform real-time and direct measurement of battery cell parameters of temperature, voltage, and AC impedance through online sensing. These parameters may be simultaneously processed using advanced probabilistic and/or fuzzy logic-based algorithms to provide an early warning for the incoming failure of battery cells in a battery pack. This technology may safeguard the LIB battery packs while allowing them to operate at or near 100% capacity in both transportation and stationary applications. | 05-30-2013 |
20160055736 | ADVANCED BATTERY EARLY WARNING AND MONITORING SYSTEM - Systems, apparatuses and methods for detecting internal cell faults using online and real-time sensing techniques, and providing an accurate and reliable early warning for the incoming failure of battery cells hours or days prior to failure. A system is configured to perform real-time and direct measurement of battery cell parameters of temperature, voltage, and AC impedance through online sensing. These parameters may be simultaneously processed using advanced probabilistic and/or fuzzy logic-based algorithms to provide an early warning for the incoming failure of battery cells in a battery pack. This technology may safeguard the LIB battery packs while allowing them to operate at or near 100% capacity in both transportation and stationary applications. | 02-25-2016 |
Patent application number | Description | Published |
20100322778 | Method and apparatus for improving turbocharger components - In one form, a turbocharger component, such as a compressor wheel or an impeller, formed of a cast material or a material made using a powder metal process, includes a surface having at least a portion thereof treated by a thermo-mechanical treatment process, such as friction stir processing. At the treated portion, the material forming the component includes a microstructure that is different than the microstructure of the material throughout the rest of the component. For example, in one form the material at the treated portion includes a homogenous microstructure while the material throughout the rest of the component includes a cast microstructure. In one or more forms, the treated portion exhibits at least one of increased strength, ductility and fatigue-resistant properties. In another form, a method is directed to providing components for a turbocharger which exhibit enhanced structural properties. However, other embodiments, forms and applications are also envisioned. | 12-23-2010 |
20130192564 | LASER SHOCK PEENING APPLIED TO FUEL SYSTEM PUMP HEAD - A fuel pump for pressurizing fuel and transporting the pressurized fuel to a common rail of an automotive engine is disclosed. The inner surface regions are processed by laser shock peening so that the fuel pump can provide a highly pressurized fuel to the common rail. The fuel pump includes an inlet check valve bore fluidly connected to a dome, the dome is fluidly connected to an outlet check valve bore, and the outlet check valve bore is fluidly connected to an outer check valve seat. A fuel-side surface of the fuel pump has a laser shock peened surface. The laser shock peened surface includes one or more of the fuel-side surface(s) of the inlet check valve bore, the dome, the outlet check valve bore, and/or the outlet check valve seat. | 08-01-2013 |
20150034214 | APPARATUS, SYSTEM, AND METHOD FOR REINFORCING A BEND IN METALLIC MATERIAL - Described herein is an apparatus for reinforcing a metallic material includes a rotatable tool that is insertable into the metallic material. The rotatable tool is configured to plastically deform the metallic material. The apparatus also includes a coolant delivery mechanism that is coupled to the rotatable tool. The coolant delivery mechanism is configured to deliver a coolant to the metallic material. | 02-05-2015 |
Patent application number | Description | Published |
20120145998 | Local Bottom Gates for Graphene and Carbon Nanotube Devices - Transistor devices having nanoscale material-based channels and techniques for the fabrication thereof are provided. In one aspect, a transistor device includes a substrate; an insulator on the substrate; a gate embedded in the insulator with a top surface of the gate being substantially coplanar with a surface of the insulator; a dielectric layer over the gate and insulator; a channel comprising a carbon nanostructure material formed on the dielectric layer over the gate, wherein the dielectric layer over the gate and the insulator provides a flat surface on which the channel is formed; and source and drain contacts connected by the channel. A method of fabricating a transistor device is also provided. | 06-14-2012 |
20120235119 | Method to Improve Nucleation of Materials on Graphene and Carbon Nanotubes - Techniques for forming a thin coating of a material on a carbon-based material are provided. In one aspect, a method for forming a thin coating on a surface of a carbon-based material is provided. The method includes the following steps. An ultra thin silicon nucleation layer is deposited to a thickness of from about two angstroms to about 10 angstroms on at least a portion of the surface of the carbon-based material to facilitate nucleation of the coating on the surface of the carbon-based material. The thin coating is deposited to a thickness of from about two angstroms to about 100 angstroms over the ultra thin silicon layer to form the thin coating on the surface of the carbon-based material. | 09-20-2012 |
20130113081 | QUANTUM CAPACITANCE GRAPHENE VARACTORS AND FABRICATION METHODS - A plate varactor includes a dielectric substrate and a first electrode embedded in a surface of the substrate. A capacitor dielectric layer is disposed over the first electrode, and a layer of graphene is formed over the dielectric layer to contribute a quantum capacitance component to the dielectric layer. An upper electrode is formed on the layer of graphene. Other embodiments and methods for fabrication are also included. | 05-09-2013 |
20150255631 | QUANTUM CAPACITANCE GRAPHENE VARACTORS AND FABRICATION METHODS - A plate varactor includes a dielectric substrate and a first electrode embedded in a surface of the substrate. A capacitor dielectric layer is disposed over the first electrode, and a layer of graphene is formed over the dielectric layer to contribute a quantum capacitance component to the dielectric layer. An upper electrode is formed on the layer of graphene. Other embodiments and methods for fabrication are also included. | 09-10-2015 |